Chart specialist Carter Worth appeared on Fast Money this week to highlight a classic bearish-to-bullish reversal pattern in UnitedHealth’s daily price chart. According to Worth, the stock has formed a double bottom over the past three months, with declining relative-strength index (RSI) readings below 40 giving way to a bullish divergence as RSI has climbed back above 50. Volume has picked up on recent advances, suggesting institutional support for a breakout above the March high. Investors should watch for a sustained move beyond that level to confirm a technical shift in trend.

After a 32% decline in 2025 that reduced UnitedHealth’s market capitalization from $541 billion in April to $297 billion by year-end, sentiment has stabilized. Sector recovery in managed care and Berkshire Hathaway’s opportunistic purchase of a multibillion-dollar stake have bolstered confidence. At current multiples—approximately 14 times forward earnings—UNH trades near its five-year average, offering a more attractive entry compared with both its own history and peers. Analysts note that any uptick in operating margin toward the company’s long-term target of 8.5% would justify higher valuation.

UnitedHealth’s upcoming Q4 earnings call on February 15 will be closely scrutinized for full-year 2026 guidance. Management has previously targeted annual revenue growth of 11%–13% and adjusted EBITDA margins of 8.0%–8.2%. Investors will evaluate whether the company can deliver sustained margin improvement in its core UnitedHealthcare business and resolve cost pressures in Optum. Clear visibility on 2026 profitability and cash-flow trends will determine whether the stock can resume an uptrend or remain range-bound.

The 32% sell-off in 2025 underscores persistent challenges. Regulatory scrutiny over pricing practices, potential expansion of government reimbursement clawbacks, and rising medical cost inflation pose headwinds. UnitedHealth’s EBITDA margin contracted by 150 basis points last year, and the company saw medical care ratio creep back above 84%. Should cost containment initiatives falter, or if legislative proposals target managed-care profitability, downside risk could intensify despite technical and valuation support.